The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Field
Pink October is drawing to a close
Throughout October, our teams rallied together with enthusiasm and solidarity for the Pink October Challenge. Thanks to their commitment: Over 590 kilometres were covered. Proudly wearing our pink T-shirts, our teams joined forces to support the charity Bouger pour...
Chronicles of a small industrialist who dreams of re-enchanting France – Episode 39
At MGA, excellence is a relay. Strong women lead the way. Curious minds rise behind them. That’s how we build the future of French industry: together. With pride. With passion. With purpose.